NanoVibronix (NAOV) Stock Price, News & Analysis

Company Overview

NanoVibronix, Inc., through its subsidiary, NanoVibronix Ltd., focuses on the manufacture and sale of noninvasive biological response-activating devices that target biofilm prevention, wound healing, and pain therapy. Its product portfolio includes UroShield, an ultrasound-based product to prevent bacterial colonization and biofilm in urinary catheters, enhance antibiotic efficacy, and decrease pain and discomfort associated with urinary catheter use. The company also offers PainShield, a patch-based therapeutic ultrasound technology to treat pain, muscle spasm, and joint contractures; and WoundShield, a patch-based therapeutic ultrasound device intended to facilitate tissue regeneration and wound healing by using ultrasound to increase local capillary perfusion and tissue oxygenation. It sells its products directly to patients, as well as through distributor agreements in the United States, Israel, Europe, Australia, India, and internationally. The company was incorporated in 2003 and is headquartered in Elmsford, New York.

Key Stats

• Today's Range: $0.70 to $0.72
• 50-Day Range: $0.53 to $0.80
• 52-Week Range: $0.52 to $2.90
• Volume: 19,072 shs
• Average Volume: 60,732 shs
• Market Capitalization: $1.94 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

NanoVibronix Stock Analysis - MarketRank™

NanoVibronix scored higher than 11% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for NanoVibronix.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of NanoVibronix is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of NanoVibronix is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

NanoVibronix has a P/B Ratio of 0.36. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.01% of the float of NanoVibronix has been sold short.

Short Interest Ratio / Days to Cover

NanoVibronix has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoVibronix has recently increased by 9.84%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

NanoVibronix does not currently pay a dividend.

Dividend Growth

NanoVibronix does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

1.01% of the float of NanoVibronix has been sold short.

Short Interest Ratio / Days to Cover

NanoVibronix has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in NanoVibronix has recently increased by 9.84%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 2.7 / 5
• News Sentiment: N/A

News Sentiment

NanoVibronix has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, NanoVibronix insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 3.60% of the stock of NanoVibronix is held by insiders.

Percentage Held by Institutions

Only 16.39% of the stock of NanoVibronix is held by institutions.

NAOV Stock Analysis - Frequently Asked Questions

How have NAOV shares performed this year?

NanoVibronix's stock was trading at $1.15 at the start of the year. Since then, NAOV stock has decreased by 39.3% and is now trading at $0.6977.
View the best growth stocks for 2024 here.

How were NanoVibronix's earnings last quarter?

NanoVibronix, Inc. (NASDAQ:NAOV) issued its quarterly earnings results on Wednesday, August, 14th. The company reported ($0.25) earnings per share for the quarter. The company had revenue of $0.82 million for the quarter. NanoVibronix had a negative trailing twelve-month return on equity of 74.98% and a negative net margin of 83.49%.

When did NanoVibronix's stock split?

NanoVibronix's stock split before market open on Thursday, October 13th 2022. The 2-1 split was announced on Thursday, October 13th 2022. The newly created shares were issued to shareholders after the market closes on Thursday, October 13th 2022. An investor that had 100 shares of stock prior to the split would have 200 shares after the split.

Who are NanoVibronix's major shareholders?

Top institutional shareholders of NanoVibronix include Armistice Capital LLC (4.92%). Insiders that own company stock include Christopher M Fashek and Aurora Cassirer.
View institutional ownership trends.

How do I buy shares of NanoVibronix?

Shares of NAOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of NanoVibronix own?

Based on aggregate information from My MarketBeat watchlists, some other companies that NanoVibronix investors own include T2 Biosystems (TTOO), ADMA Biologics (ADMA), Co-Diagnostics (CODX), Inovio Pharmaceuticals (INO), Tonix Pharmaceuticals (TNXP) and BIO-key International (BKYI).

Company Calendar

• Last Earnings: 8/14/2024
• Today: 9/18/2024
• Next Earnings (Estimated): 11/11/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Surgical appliances & supplies
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:NAOV
• CUSIP: N/A
• CIK: 1326706
• Web: www.nanovibronix.com
• Phone: (914) 233-3004
• Fax: 914-376-6111
• Employees: 20
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.69)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-3,710,000.00
• Net Margins: -83.49%
• Pretax Margin: -82.75%
• Return on Equity: -74.98%
• Return on Assets: -43.38%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 2.11
• Quick Ratio: 1.16

Sales & Book Value

• Annual Sales: $3.37 million
• Price / Sales: 0.58
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.95 per share
• Price / Book: 0.36

Miscellaneous

• Outstanding Shares: 2,784,000
• Free Float: 2,684,000
• Market Cap: $1.94 million
• Optionable: Not Optionable
• Beta: 1.50